	US 12,251,364 B2
	Treating non-alcoholic steatohepatitis with cck inhibitors
Jill P. Smith, Camp Hill, PA (US)
Assigned to Georgetown University, Washington, DC (US)
Appl. No. 17/291,681
Filed by GEORGETOWN UNIVERSITY, Washington, DC (US)
PCT Filed Nov. 5, 2019, PCT No. PCT/US2019/059833 § 371(c)(1), (2) Date May 6, 2021, PCT Pub. No. WO2020/097054, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/756,384, filed on Nov. 6, 2018.
Prior Publication US 2022/0000819 A1, Jan. 6, 2022
Int. Cl. A61K 31/197 (2006.01); A61K 31/355 (2006.01); A61P 1/16 (2006.01)

CPC A61K 31/197 (2013.01) [A61K 31/355 (2013.01); A61P 1/16 (2018.01)]

10 Claims

1. A method for treating nonalcoholic steatohepatitis (NASH) in a subject, comprising administering to a subject having NASH an effective amount of a CCK receptor inhibitor, wherein the CCK receptor inhibitor is proglumide.